Endogenous processing of LMP1 CTL epitopes encoded by Vacc.polyLMP.

(A) LMP1 epitope-specific lysis by YLL- and YLQ-specific CTL lines derived from 2 healthy virus carriers (donor no. 1 and donor no. 2). Peptide-sensitized and uncoated HLA A2–positive PHA blasts were used as target cells in the CTL assay. (B) HLA A2–positive fibroblasts were infected with either Vacc.polyLMP or Vacc.TK⁻ for 18 hours and then exposed to YLL- and YLQ-specific CTL lines from donors donor no. 1 and donor no. 2. An effector-target ratio of 10:1 was used for both assays.